Table 1.
Characteristics of the children with Klebsiella pneumoniae bloodstream infection
| Variable | All | ESBL-KPb | Non-ESBL-KP | p value |
|---|---|---|---|---|
| Number of children (%) | N = 410 | n = 339/410 (83 %) | n = 71/410 (17 %) | - |
| Male: female | 212: 198 | 170: 169 | 1.77 | 0.17 |
| Median (IQR) age in months | 5 (2–16) | 5 (2–5) | 10 (2–29) | 0.12 |
| Median weight-for-age z-score (IQR) | −2 (−4 to −1) | −2 (−4 to −1) | −1 (−3 to −1) | 0.02 |
| Moderate under-weight-for-age n/N (%) |
78/410 (19.0) | 66/339 (19.5) | 12 /71 (16.9) | 0.14 |
| Severe underweight-for-age n/N (%) | 163/410 (39.8) | 143/339 (42.2) | 20 /71 (28.2) | 0.01 |
| HIV-infectiona (%) | (n = 288) | (n = 249) | (n = 39) | |
| 82 (28.5) | 79 (31.7 %) | 3 (7.7 %) | 0.004 | |
| Exposure to a selection of antibioticsc | 319/388 (82.2) | 287/319 (90) | 31/68 (46.4) | <0.0001 |
| 2nd - 4th generation Cephalosporins | 205/388 (52.8) | 190/205 (92.8) | 15 /69 (17.8) | <0.0001 |
| Aminoglycosides | 227/388 (58.5) | 206/319 (64.6) | 21/69 (30.4) | <0.0001 |
| Cotrimoxazole | 96/388 (24.7) | 91/319 (28.5) | 5/69 (7.3) | 0.001 |
| Carbapenems | 69/388 (17.8) | 65/319 (20.4) | 4 /69 (5.8) | 0.004 |
| Piperacillin-tazobactam | 107/388 (27.6) | 95/319 (29.8) | 12/69 (17.4) | 0.04 |
| Fluoroquinolones | 55/388 (14.2) | 48/319 (15.1) | 7/69 (10.1) | 0.29 |
KP Klebsiella pneumoniae, IQR interquartile range, n/N stratum specific proportions
aHIV prevalence known in 288 children
bESBL-KP: extended-spectrum-β-lactamase-producing Klebsiella pneumoniae
cExposure to the following antibiotics within the last 12 months before the KP bloodstream infection: 2nd and/or 3rd and/or 4th generation cephalosporins, macrolides, fluoroquinolones, cotrimoxazole, aminoglycosides, piperacillin-tazobactam, and carbapenems